109 Innovative 3D models for understanding mechanisms underlying lung diseases: powerful tools for translational research 181. Jones MG, Andriotis OG, Roberts JJ, Lunn K, Tear VJ, Cao L, Ask K, Smart DE, Bonfanti A, Johnson P, Alzetani A, Conforti F, Doherty R, Lai CY, Johnson B, Bourdakos KN, Fletcher SV, Marshall BG, Jogai S, Brereton CJ, Chee SJ, Ottensmeier CH, Sime P, Gauldie J, Kolb M, Mahajan S, Fabre A, Bhaskar A, Jarolimek W, Richeldi L, O’Reilly KM, Monk PD, Thurner PJ, Davies DE. Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. eLife 2018: 7. 182. Berhan A, Harris T, Jaffar J, Jativa F, Langenbach S, Lonnstedt I, Alhamdoosh M, Ng M, Lee P, Westall G, Wilson N, Wilson M, Stewart AG. Cellular Microenvironment Stiffness Regulates Eicosanoid Production and Signaling Pathways. Am J Respir Cell Mol Biol 2020: 63(6): 819-830. 183. Wallmeier J, Nielsen KG, Kuehni CE, Lucas JS, Leigh MW, Zariwala MA, Omran H. Motile ciliopathies. Nat Rev Dis Pri 2020: 6(1): 77. 184. Lee DDH, Cardinale D, Nigro E, Butler CR, Rutman A, Fassad MR, Hirst RA, Moulding D, Agrotis A, Forsythe E, Peckham D, Robson E, Smith CM, Somavarapu S, Beales PL, Hart SL, Janes SM, Mitchison HM, Ketteler R, Hynds RE, O’Callaghan C. Higher throughput drug screening for rare respiratory diseases: readthrough therapy in primary ciliary dyskinesia. Eur Respir J 2021: 58(4). 185. Hynds RE, Bonfanti P, Janes SM. Regenerating human epithelia with cultured stem cells: feeder cells, organoids and beyond. EMBO Mol Med 2018: 10(2): 139-150. 186. Pan E, Bogumil D, Cortessis V, Yu S, Nieva J. A Systematic Review of the Efficacy of Preclinical Models of Lung Cancer Drugs. Front Oncol 2020: 10: 591. 187. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Rev Drug Discov 2010: 9(3): 203-214. 188. Movia D, Prina-Mello A. Preclinical Development of Orally Inhaled Drugs (OIDs)- Are Animal Models Predictive or Shall We Move Towards In Vitro Non-Animal Models? Animals (Basel) 2020: 10(8). 189. Movia D, Bruni-Favier S, Prina-Mello A. In vitro Alternatives to Acute Inhalation Toxicity Studies in Animal Models-A Perspective. Front Bioeng Biotechnol 2020: 8: 549. 4
RkJQdWJsaXNoZXIy MTk4NDMw